Safety and immunogenicity of mRNA-1345 RSV revaccination at least 12 months following primary vaccination with a licensed protein subunit RSV vaccine
Mihir Desai, Jose Cardona, Shishir Khetan, Shraddha Mehta, Archana Kapoor, Aghogho Okparavero, Zhantao Lin, and Frances Priddy
This oral presentation was presented at ESCMID 2026 which was held in Munich, Germany from 17-21 April, 2026. This page will not be available beyond 30 days after the congress has closed.